Oesophageal squamous cell carcinoma: II. A critical review of radiotherapy

Earlam, Richard; Cunha-Melo, José Renan

doi:10.1002/bjs.1800670702

Cited by 421 publications

(86 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Esophageal cancer is one of the most difficult malignancies to cure, and the prognosis for these patients is poor (1)(2)(3). Although surgery is the main curative treatment for these tumors, chemoradiotherapy (CRT) was identified as a viable option for the treatment of esophageal carcinoma.…”

Section: Introductionmentioning

confidence: 99%

Clinical significance of GLUT-1 expression in patients with esophageal cancer treated with concurrent chemoradiotherapy

et al. 2010

View full text Add to dashboard Cite

Abstract. This study aimed to investigate whether glucose transporter-1 (GLUT-1) expression in a pretreatment esophageal cancer biopsy was predictive of clinical outcomes in patients with esophageal cancer undergoing concurrent chemoradiotherapy (CRT). A total of 25 patients with esophageal cancer treated with concurrent CRT were reviewed. Radiotherapy was administered up to total doses of 40-66.6 Gy (median 66.6 Gy) with a single fraction of 1.8-2 Gy. Regarding chemotherapy, cisplatin (80 mg/m 2 on day 1) and 5-fluorouracil (800 mg/m 2 on days 2-6) were used concurrently with radiotherapy, every 3-4 weeks for a total of 1-2 courses. Tissue samples from esophageal carcinoma were obtained from the 25 patients by biopsy prior to concurrent CRT, and a semiquantitative analysis of GLUT-1 expression was performed using immunohistochemical staining. High GLUT-1 expression was observed in 7 of 25 (28%) patients, and GLUT-1 expression was significantly correlated with clinical T stage (p=0.0454), clinical N stage (p=0.0324) and initial response to CRT (p=0.0185). Patients with a high GLUT-1 expression had significantly poorer local control (LC) (5-year LC 28.6%) than those with a low expression (5-year LC 73.4%, p<005). Multivariate analysis revealed that GLUT-1 and the number of chemotherapy courses were independent prognostic factors for LC. Patients with a high GLUT-1 expression had significantly lower recurrence-free survival (RFS) compared to those with a low GLUT-1 expression (p=0.0405). Multivariate analysis revealed that GLUT-1, the number of chemotherapy courses and clinical M stage were independent prognostic factors for RFS. GLUT-1 expression was significantly correlated with clinical T stage, clinical N stage and initial response to concurrent CRT, and was predictive of LC and RFS for patients with esophageal cancer treated with concurrent CRT.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical significance of GLUT-1 expression in patients with esophageal cancer treated with concurrent chemoradiotherapy

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Could this difference in validity be ascribed to the difference in indications instead of genuine effectiveness of the treatment method? Despite the reports of Earlam and Cunha-Melo [2,3] , who compiled the result of treatment of esophageal carcinoma in the literature before 1979, the 5-year survival rate of 8489 patients in 49 institutes who had received radiation therapy before 1979 was 6% ± 6%. In contrast, the 83, 783 patients in 122 institutes operated upon in the same interval had a 5-year survival rate of 4% ± 3%.…”

Section: Introductionmentioning

confidence: 93%

“…However, it cannot be refuted that surgeons treat far earlier lesions than radiotherapists do. As early as 1980, Earlam et al [2] and Cunha-Meloet al [2,3] had expressed their doubts about the superiority of surgery, for which the better survival rates could have been due to the earlier disease. If surgeons and radiotherapists were on equal footing, what kind of result may they yield?…”

Section: Comparison Of Surgery With Radiotherapymentioning

confidence: 99%

Radiotherapy of 180 cases of operable esophageal carcinoma

Chen¹,

Yang²,

Yin³

2011

WJG

View full text Add to dashboard Cite

“…Before 1990, the standard treatment for patients with locoregional esophageal cancer was esophagogastrectomy [1]. Many patients, however, were not operated on, because of poor medical conditions, extensive disease, or localization not permitting adequate surgery, and were treated with radiotherapy [2,3]. Both treatment modalities had unsatisfactory results with 2-year survival rates being about 10% [4].…”

Section: Introductionmentioning

confidence: 99%

Retrospective evaluation of combined modality treatment and prognostic factors in patients with esophageal cancer

et al. 2005

View full text Add to dashboard Cite

The influence of prognostic factors and combined modality treatment on survival was evaluated retrospectively for 156 patients with esophageal cancer receiving radiotherapy in different modalities between 1991 and 2001 at the University of Heidelberg and the Universitä tsklinikum Mannheim. Forty-six patients (29.5%) were treated with radiotherapy alone, 74 patients (47.4%) had combined radiochemotherapy and 36 patients (23.1%) were operated on after receiving neoadjuvant radiochemotherapy. The median follow-up time was 10 months. Female patients showed a significantly better overall survival compared with male patients (p0/0.031), younger patients (age 5/60 years) a significantly better survival compared to older patients (age /60 years) (p 0/0.02). Patients with hemoglobin concentration /13.4 g/dl before therapy (median hemoglobin concentration) had a significantly better overall survival than patients with lower hemoglobin concentration (p0/0.044). Patients who received combined radiochemotherapy (with or without operation) had a survival advantage compared with radiotherapy alone. Overall survival after neoadjuvant treatment followed by operation was significantly better than in the two other groups, median survival times were 20 vs. 9 (RCHT) vs. 8 months (RT) (p 0/0.003). The data presented show for the first time that hemoglobin concentration in addition to gender and age was a prognostic factor for patients with esophageal cancer. A low hemoglobin value was a negative predictor.

show abstract

Oesophageal squamous cell carcinoma: II. A critical review of radiotherapy

Cited by 421 publications

References 28 publications

Clinical significance of GLUT-1 expression in patients with esophageal cancer treated with concurrent chemoradiotherapy

Clinical significance of GLUT-1 expression in patients with esophageal cancer treated with concurrent chemoradiotherapy

Radiotherapy of 180 cases of operable esophageal carcinoma

Retrospective evaluation of combined modality treatment and prognostic factors in patients with esophageal cancer

Contact Info

Product

Resources

About